Company Overview: ARDX

Upcoming Projects (ARDX)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (ARDX)

Getting a clinician's perspective on Ardelyx's XPHOZAH (tenapanor) and the company's decision to not file for TDAPA
Ticker: ARDX
Executed On: Aug 21, 2024 at 05:00 PM EDT
Checking In With a Prescriber of Ardelyx’s XPHOZAH (tenapanor) as a Treatment for Hyperphosphatemia in Patients with Chronic Kidney Disease
Ticker: ARDX
Executed On: Mar 19, 2024 at 09:00 AM EDT
Investigating Ardelyx’s XPHOZAH (tenapanor) as a treatment for Hyperphosphatemia in patients with Chronic Kidney Disease.
Ticker: ARDX
Executed On: Dec 06, 2023 at 10:00 AM EST
Evaluating Ardelyx, Inc.'s Xphozah (tenapanor) for the Treatment of Hyperphosphatemia with an Anticipated PDUFA Date of October 17, 2023
Ticker: ARDX
Executed On: Sep 26, 2023 at 06:00 PM EDT
Discussing the Phase 3 results for Ardelyx' tenapanor for the control of serum phosphorus in adult patients with Chronic kidney disease undergoing dialysis
Ticker: ARDX
Executed On: Nov 30, 2022 at 05:30 PM EST

Expired Projects (ARDX)

Assessing Tenapanor's safety/ efficacy profile in IBS-C ahead of the PDUFA date September 12, 2019
Ticker: ARDX
Execute By: Sep 11, 2019

Upcoming & Overdue Catalysts (ARDX)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (ARDX)

Ardelyx, Inc. Expected to Release Data in First Half of 2017 from Onset-of-Action Study Evaluating the Effect of RDX7675 on the Rate of Blood Potassium Lowering, Along with Safety and Efficacy, in Patients with Hyperkalemia - Discontinued
Tickers: ARDX, KERX
Occurred on: Nov 21, 2017
Ardelyx, Inc. Expected to Release Clinical Data by Late 2017 from T3MPO-2 Trial with Tenapanor in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
Tickers: ARDX, SGYP, IRWD
Occurred on: Oct 16, 2017
Ardelyx, Inc. to Submit Detailed Results from Its First Phase 3 Trial Of Tenapanor for Hyperphosphatemia in End-Stage Renal Disease (ESRD) at The American Society Of Nephrology Kidney Week
Tickers: ARDX, KERX
Occurred on: Oct 11, 2017
Ardelyx, Inc. Expected to Release Clinical Data by Mid-2017 from T3MPO-1 Trial with Tenapanor in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
Tickers: ARDX, SGYP, IRWD
Occurred on: May 12, 2017
Ardelyx'S Plans to Initiate The Second Phase 3 Study of Tenapanor for The Treatment Of Hyperphosphatemia in ESRD Patients on Dialysis in Mid-2017
Tickers: ARDX, KERX
Occurred on: Feb 15, 2017
Ardelyx (ARDX) Presents Top-Line Phase 3 Results Evaluating Tenapanor in End-Stage Renal Disease (ESRD) with Hyperphosphatemia
Ticker: ARDX
Occurred on: Feb 15, 2017
Ardelyx, Inc. Announces the Initiation of a Three Part Phase 3 Clinical Trial Evaluating RDX7675 In Patients with Hyperkalemia
Tickers: ARDX, KERX
Occurred on: Jan 03, 2017
Ardelyx Receives Notice of Allowance of Composition of Matter Patent Covering its Novel Potassium Binder RDX227675
Ticker: ARDX
Occurred on: Aug 01, 2016

Strategic Initiatives (ARDX)

Don’t see a strategic initiative related to the company you care about? Create your own!

ARDX Overview